Cambridge Healthtech Institute’s 9th Annual

Oligo CMC, Analytics & Manufacturing

Driving Quality, Efficiency, and Commercial Readiness through Advanced Analytics and Scalable Manufacturing

March 18-19, 2027

Cambridge Healthtech Institute’s Oligo CMC, Analytics & Manufacturing conference provides a comprehensive forum for addressing the evolving challenges involved in developing, characterizing, scaling, and commercializing oligonucleotide therapeutics. The program brings together industry experts to share practical strategies across analytical development, impurity control, formulation, product quality, comparability, and lifecycle management, including considerations for complex conjugates and emerging modalities. Sessions will explore enzymatic synthesis, sustainable manufacturing, automation, continuous processing, digitalization, AI and ML, Quality by Design (QbD), and process-analytical technologies. Attendees will gain actionable insights into navigating global regulatory expectations, accelerating technology transfer, improving manufacturing efficiency, and achieving scalable, commercially-ready production.

Coverage will include, but is not limited to:

Optimizing CMC strategies for novel oligonucleotide therapeutics
Innovations in analytical development and characterization
Developing robust analytical methods for impurity identification and control
Enabling CMC, analytical development, and manufacturing for complex oligonucleotide conjugates and emerging modalities
Formulation and drug product development for advanced oligonucleotides
Advancing scalable manufacturing from clinical development to commercial production
Harnessing enzymatic oligonucleotide synthesis and innovative manufacturing technologies
Driving sustainable and green manufacturing through process innovation
Improving manufacturing efficiency through automation, continuous processing, and digitalization
Leveraging digitalization, AI and ML across CMC, analytical development, and manufacturing
Implementing Quality by Design (QbD), control strategies, and process analytical technologies (PAT)
Navigating evolving global regulatory expectations for oligonucleotide CMC
Strategies for technology transfer and commercial manufacturing readiness
Ensuring product quality, comparability, and lifecycle management

The deadline for priority consideration is September 4th 2026.

Submit a Proposal »

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: